Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-42692507
- Development stage
- Phase 1
- Lead developer
- Janssen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JNJ-42692507 is an investigational small molecule drug developed by Janssen (a Johnson & Johnson company). It has been studied in early-phase clinical trials to investigate its pharmacokinetics, often alongside other compounds such as JNJ-42396302 and JNJ-53773187, in healthy male participants. The available data indicate that it was administered orally as a single dose in these studies. Specific details about its mechanism of action, therapeutic target, or primary indication have not been disclosed in the referenced sources[2][3][5]. There is no evidence of advanced clinical development or approval for any disease.
Beyond the preview
Go deeper on JNJ-42692507.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-42692507.